R-CEOP Therapy - 21 days. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Regulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| Treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy. |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.
| Organizations | Biomarkers | Cancer types | Therapies |
|---|